The FDA approved Merck’s Welireg (belzutifan) plus Keytruda (pembrolizumab) as adjuvant therapy for adults with clear cell Renal Cell Carcinoma (RCC) at risk of recurrence after nephrectomy, based on the Phase III LITESPARK-022 trial in 1,841 patients. At a prespecified interim analysis, the combination delivered a 28% disease-free survival benefit, with 186 events versus 246 for Keytruda plus placebo; median DFS was not reached in either arm and OS data were not yet mature.

Why It Matters To Oncology

• This adds a new post-surgical option for high-risk clear cell RCC, expanding adjuvant treatment beyond PD-1 monotherapy.

• The approval also covers the subcutaneous formulation, Keytruda Qlex, potentially broadening administration options in practice.

• Mechanistically, the pairing combines PD-1 blockade with HIF-2α inhibition, a notable drug discovery signal for earlier-line RCC combination strategies.

The Financials

• The decision followed a priority review, underscoring the commercial and clinical importance of moving Welireg upstream in RCC.

• Welireg was already approved in late 2023 for previously treated advanced RCC, and this label expansion could materially widen its eligible patient population.

• For Keytruda, this marks a fourth kidney cancer approval, reinforcing Merck’s franchise in RCC across adjuvant and first-line advanced settings.

What They're Saying

• The LITESPARK-022 data support a meaningful DFS improvement, but the absence of mature OS data will remain a focus for clinicians weighing adjuvant intensification.

• Keytruda already has a post-nephrectomy foothold from KEYNOTE-564, where it showed a 38% overall survival improvement in high-risk disease.

• Some RCC experts have previously said they would stick with Opdivo-based immuno-oncology combinations in RCC because of ongoing uncertainty around sequencing.

What's Next

• Clinicians will watch for mature OS readouts from LITESPARK-022 to determine how strongly this regimen reshapes adjuvant RCC standards.

• Real-world uptake may hinge on tolerability, sequencing decisions, and whether clinicians favor combination adjuvant therapy over established single-agent PD-1 use.

• For drug discovery, the approval strengthens interest in HIF-2α-based combinations and earlier-disease-setting development in kidney cancer.